Mirum Pharmaceuticals reports Q4 revenue $69.554M, consensus $67.91M

“2023 was a landmark year for Mirum as we significantly expanded our commercial footprint, realizing $179 million in net product sales, and achieved another year of strong global LIVMARLI growth. We also successfully integrated CHOLBAM and CHENODAL into our portfolio, which strengthened our position as a leader in rare disease,” said Chris Peetz, chief executive officer at Mirum. “In 2024, we look forward to further expanding the reach of our approved medicines, potential LIVMARLI and CHENODAL label expansions and interim analyses for our volixibat adult indications. Operationally and financially, we are well positioned for this next phase of growth and remain committed to our mission of delivering life changing medicines to patients in need.”